BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16043360)

  • 1. Natural selection in neoplastic progression of Barrett's esophagus.
    Maley CC; Reid BJ
    Semin Cancer Biol; 2005 Dec; 15(6):474-83. PubMed ID: 16043360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic diversity during the development of Barrett's oesophagus-associated adenocarcinoma: how, when and why?
    Graham TA; McDonald SA
    Biochem Soc Trans; 2010 Apr; 38(2):374-9. PubMed ID: 20298186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multistage carcinogenesis in Barrett's esophagus.
    Maley CC
    Cancer Lett; 2007 Jan; 245(1-2):22-32. PubMed ID: 16713672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular markers and genetics in cancer development.
    Hormi-Carver K; Souza RF
    Surg Oncol Clin N Am; 2009 Jul; 18(3):453-67. PubMed ID: 19500736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma.
    Brabender J; Marjoram P; Lord RV; Metzger R; Salonga D; Vallböhmer D; Schäfer H; Danenberg KD; Danenberg PV; Selaru FM; Baldus SE; Hölscher AH; Meltzer SJ; Schneider PM
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2113-7. PubMed ID: 16172218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
    Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
    Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 and neoplastic progression in Barrett's esophagus.
    Reid BJ
    Am J Gastroenterol; 2001 May; 96(5):1321-3. PubMed ID: 11374661
    [No Abstract]   [Full Text] [Related]  

  • 8. Advances in gene chip technique in Barrett's metaplasia and adenocarcinoma.
    Wang XW; Gao HJ; Fang DC
    J Dig Dis; 2008 May; 9(2):68-71. PubMed ID: 18419638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic clonal diversity predicts progression to esophageal adenocarcinoma.
    Maley CC; Galipeau PC; Finley JC; Wongsurawat VJ; Li X; Sanchez CA; Paulson TG; Blount PL; Risques RA; Rabinovitch PS; Reid BJ
    Nat Genet; 2006 Apr; 38(4):468-73. PubMed ID: 16565718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Barrett's esophagus: the biology of neoplastic progression.
    Neshat K; Sanchez CA; Galipeau PC; Levine DS; Reid BJ
    Gastroenterol Clin Biol; 1994; 18(1 Pt 2):D71-6. PubMed ID: 8013790
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular biology of Barrett's cancer.
    Atherfold PA; Jankowski JA
    Best Pract Res Clin Gastroenterol; 2006; 20(5):813-27. PubMed ID: 16997163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromosomal instability in Barrett's esophagus is related to telomere shortening.
    Finley JC; Reid BJ; Odze RD; Sanchez CA; Galipeau P; Li X; Self SG; Gollahon KA; Blount PL; Rabinovitch PS
    Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1451-7. PubMed ID: 16896031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural selection: The evolution of cancer.
    Goymer P
    Nature; 2008 Aug; 454(7208):1046-8. PubMed ID: 18756229
    [No Abstract]   [Full Text] [Related]  

  • 14. No association between hOGG1, XRCC1, and XPD polymorphisms and risk of reflux esophagitis, Barrett's esophagus, or esophageal adenocarcinoma: results from the factors influencing the Barrett's adenocarcinoma relationship case-control study.
    Ferguson HR; Wild CP; Anderson LA; Murphy SJ; Johnston BT; Murray LJ; Watson RG; McGuigan J; Reynolds JV; Hardie LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):736-9. PubMed ID: 18349297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studying Cancer Evolution in Barrett's Esophagus and Esophageal Adenocarcinoma.
    Paulson TG
    Adv Exp Med Biol; 2016; 908():213-36. PubMed ID: 27573774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 in esophageal adenocarcinoma: a critical reassessment of mutation frequency and identification of 72Arg as the dominant allele.
    Chung SM; Kao J; Hyjek E; Chen YT
    Int J Oncol; 2007 Dec; 31(6):1351-5. PubMed ID: 17982662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical use of p53 in Barrett's esophagus.
    Keswani RN; Noffsinger A; Waxman I; Bissonnette M
    Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1243-9. PubMed ID: 16835318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Confocal laser scanning fluorescence microscopy for in vivo determination of microvessel density in Barrett's esophagus.
    Becker V; Vieth M; Bajbouj M; Schmid RM; Meining A
    Endoscopy; 2008 Nov; 40(11):888-91. PubMed ID: 19009480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Barrett's esophagus: can biomarkers predict progression to malignancy?
    Tischoff I; Tannapfel A
    Expert Rev Gastroenterol Hepatol; 2008 Oct; 2(5):653-63. PubMed ID: 19072343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.